Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. Aarhus University Hospital, Aarhus, Denmark

Survival: 7.8 months
Toxicity Grade: 4
Treatments: Immunotherapy
Country: Denmark
City/State/Province: Aarhus
Hospital: Aarhus University Hospital
Journal: Link
Date: 12/2002

Patients: This Phase II study involved 41 patients with metastatic melanoma. The median age was 56.

Treatment: The treatment consisted of the drug histamine dihydrochloride and two immunotherapy agents: interleukin-2 and interferon-alpha.

Toxicity: Grade 3-4 toxicities included altered hearing, anemia, cardiovascular, diarrhea, infection, lethargy, nausea, pulmonary, and vomiting.

Results: The overal median survival was 7.8 months.

Support: The study was supported by grants from Maxim Pharmaceuticals, Chiron, and Schering Plough. Maxim manufactures or markets histamine dihydrochloride. Chiron markets or manufactures interleukin-2. Schering markets or manufactures interferon-alpha2B.

Correspondence: H. Schmidt, MD

E-mail to a Friend Email Physician More Information